Protagonist Therapeutics Inc (PTGX)
41.04
-1.63
(-3.82%)
USD |
NASDAQ |
Nov 14, 16:00
41.04
0.00 (0.00%)
After-Hours: 20:00
Protagonist Therapeutics Cash from Investing (Quarterly): -208.71M for Sept. 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -208.71M |
| June 30, 2024 | -88.12M |
| March 31, 2024 | 6.071M |
| December 31, 2023 | -61.29M |
| September 30, 2023 | -13.56M |
| June 30, 2023 | 25.76M |
| March 31, 2023 | 9.826M |
| December 31, 2022 | 3.935M |
| September 30, 2022 | 57.28M |
| June 30, 2022 | 34.73M |
| March 31, 2022 | -4.476M |
| December 31, 2021 | 27.87M |
| September 30, 2021 | -44.71M |
| June 30, 2021 | 7.773M |
| March 31, 2021 | -6.793M |
| December 31, 2020 | -74.40M |
| September 30, 2020 | -54.12M |
| June 30, 2020 | -5.171M |
| March 31, 2020 | 42.73M |
| December 31, 2019 | -12.55M |
| Date | Value |
|---|---|
| September 30, 2019 | -32.04M |
| June 30, 2019 | -13.22M |
| March 31, 2019 | 4.108M |
| December 31, 2018 | 4.549M |
| September 30, 2018 | 9.917M |
| June 30, 2018 | 9.591M |
| March 31, 2018 | -21.84M |
| December 31, 2017 | 4.752M |
| September 30, 2017 | -0.772M |
| June 30, 2017 | 13.09M |
| March 31, 2017 | -1.25M |
| December 31, 2016 | -64.32M |
| September 30, 2016 | 3.884M |
| June 30, 2016 | -6.034M |
| March 31, 2016 | 7.147M |
| December 31, 2015 | -8.085M |
| September 30, 2015 | -0.113M |
| June 30, 2015 | -0.061M |
| March 31, 2015 | -0.005M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-208.71M
Minimum
Sep 2024
57.28M
Maximum
Sep 2022
-17.90M
Average
-4.824M
Median
Cash from Investing (Quarterly) Benchmarks
| Johnson & Johnson | -3.128B |
| Assembly Biosciences Inc | 5.107M |
| Precision BioSciences Inc | -0.064M |
| Entrada Therapeutics Inc | -82.93M |
| NovaBay Pharmaceuticals Inc | -0.002M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -27.86M |
| Cash from Financing (Quarterly) | 12.05M |
| Free Cash Flow | 229.23M |
| Free Cash Flow Per Share (Quarterly) | -0.4636 |
| Free Cash Flow to Equity (Quarterly) | -28.64M |
| Free Cash Flow to Firm (Quarterly) | -28.64M |
| Free Cash Flow Yield | 9.04% |